Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3831 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Merck heart drug reduces flushing

Flushing, characterized by redness of the skin with warming or burning on the face and neck caused by the dilation of blood vessels near the skin, is a

New Reata cancer drug reduces tumors

Research showed that RTA 402 protected mice from the development of invasive lung tumors following exposure to vinyl carbamate. This chemical causes mice to develop a large number

Alteon compound reduces heart injury in mice

ALT-2074 formerly BXT-51072, was licensed by Oxis Pharmaceuticals to Alteon in September 2004. It is a low molecular weight oral drug that mimics the antioxidant enzyme glutathione peroxidase.

Synta skin cancer drug granted fast track

In a recently completed, phase IIb trial in patients with metastatic malignant melanoma, treatment with STA-4783 plus paclitaxel achieved the primary endpoint of increasing progression-free survival. “Metastatic melanoma

Ambrilia enters license agreement with Teva Europe

Teva Europe is a subsidiary of the global generic pharmaceutical leader Teva Pharmaceutical Industries and is octreotide's licensee for France, Germany, Benelux, Spain and Scandinavia. The agreement comprises

Novalar dental anesthetic is effective

The study was designed to evaluate the safety and efficacy of NV-101 in the reversal of soft tissue anesthesia in pediatric subjects undergoing dental or periodontal maintenance procedures